All Outputs (5)

Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study (2022)
Journal Article
Liu, Z., Le, K., Zhou, X., Alexander, J. L., Lin, S., Bewshea, C., …Powell, N. (2023). Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study. The Lancet Gastroenterology & Hepatology, 8(2), 145-156. https://doi.org/10.1016/S2468-1253%2822%2900389-2

Background Anti-TNF drugs, such as infliximab, are associated with attenuated antibody responses after SARS-CoV-2 vaccination. We aimed to determine how the anti-TNF drug infliximab and the anti-integrin drug vedolizumab affect vaccine-induced neutr... Read More about Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.

British Society of Gastroenterology interim framework for addressing the COVID-19-related backlog in inflammatory bowel disease colorectal cancer surveillance (2022)
Journal Article
Churchhouse, A. M. D., Moffat, V. E. L., Selinger, C. P., Lamb, C. A., Thornton, M. J., Penman, I., & Din, S. (2023). British Society of Gastroenterology interim framework for addressing the COVID-19-related backlog in inflammatory bowel disease colorectal cancer surveillance. Gut, 72(9), 1631-1634. https://doi.org/10.1136/gutjnl-2022-328309

Imaging in inflammatory bowel disease: current and future perspectives (2022)
Journal Article
Shaban, N., Hoad, C. L., Naim, I., Alshammari, M., Radford, S. J., Clarke, C., …Moran, G. (2022). Imaging in inflammatory bowel disease: current and future perspectives. Frontline Gastroenterology, 13(e1), E28-E34. https://doi.org/10.1136/flgastro-2022-102117

The use of cross-sectional imaging and ultrasonography has long complemented endoscopic assessment of inflammatory bowel disease (IBD). Clinical symptoms alone are often not enough to assess disease activity, so a reliance on non-invasive techniques... Read More about Imaging in inflammatory bowel disease: current and future perspectives.

Tacrolimus (FK506) for induction of remission in corticosteroid-refractory ulcerative colitis (2022)
Journal Article
Gordon, M., Sinopoulou, V., Akobeng, A. K., Pana, M., Gasiea, R., & Moran, G. W. (2022). Tacrolimus (FK506) for induction of remission in corticosteroid-refractory ulcerative colitis. Cochrane Library, 2022(4), 1-55. https://doi.org/10.1002/14651858.CD007216.pub2

Background: There are a limited number of treatment options for people with corticosteroid-refractory ulcerative colitis. Animal models of inflammatory bowel disease and uncontrolled studies in humans suggest that tacrolimus may be an effective treat... Read More about Tacrolimus (FK506) for induction of remission in corticosteroid-refractory ulcerative colitis.

Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab (2022)
Journal Article
Lin, S., Kennedy, N. A., Saifuddin, A., Sandoval, D. M., Reynolds, C. J., Castro Seoane, R., …Jones, G. (2022). Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. Nature Communications, 13, Article 1379. https://doi.org/10.1038/s41467-022-28517-z

Anti tumour necrosis factor (anti-TNF) drugs increase the risk of serious respiratory infection and impair protective immunity following pneumococcal and influenza vaccination. Here we report SARS-CoV-2 vaccine-induced immune responses and breakthrou... Read More about Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.